Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes (ALKS) reported strong financial results for Q4 and full-year 2024, with total revenues of $1.56 billion. The company achieved 18% year-over-year growth in proprietary product net sales, reaching over $1 billion. Key highlights include:
- GAAP Net Income from continuing operations of $372.1 million ($2.20 per share)
- Total proprietary net sales reached $1.08 billion
- Year-end cash position of $824.8 million
- Company became debt-free after retiring $290 million in debt
For 2025, Alkermes provided financial guidance including:
- Total revenue expectations of $1.34-1.43 billion
- GAAP Net Income of $175-205 million
- EBITDA guidance of $215-245 million
The company is advancing its neuroscience pipeline, with ALKS 2680 Phase 2 studies in narcolepsy ongoing and data expected in H2 2025.
Alkermes (ALKS) has announced it will host a conference call and webcast on February 12, 2025, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2024 financial results. During the presentation, management will also outline financial expectations for 2025 and provide a company update.
The event will be accessible through the company's website investor section, with a conference call available at +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international participants. A replay will be available approximately two hours after the event.
Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Alkermes plc (Nasdaq: ALKS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Richard Pops will deliver a corporate overview and update on Wednesday, Jan. 15, 2025, at 11:15 a.m. PST, followed by a Q&A session. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days.
Alkermes is a global biopharmaceutical company focused on neuroscience innovation. Their portfolio includes commercial products treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company's pipeline features clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia. Based in Ireland, Alkermes maintains a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.
Alkermes plc (Nasdaq: ALKS) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 10:25 a.m. ET and the Piper Sandler 36th Annual Healthcare Conference on December 4 at 4:00 p.m. ET.
The presentations will be accessible via live webcasts on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Alkermes plc (Nasdaq: ALKS) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel Healthcare Conference on November 18 at 8:35 a.m. ET and the Jefferies London Healthcare Conference on November 19 at 8:00 a.m. ET. Live webcasts will be available on Alkermes' website under the Investors tab and archived for 14 days.
Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Alkermes announced presentations at two key scientific conferences, showcasing research on LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil), and ALKS 2680. At the 37th Annual Psych Congress and the 2024 Neuroscience Education Institute Congress, Alkermes presented 12 posters, including a study on healthcare resource utilization in patients with schizophrenia and bipolar I disorder after LYBALVI initiation. The study revealed significant reductions in inpatient admissions and emergency department visits. Limitations include potential data omissions and coding errors. Additionally, safety and efficacy data from a phase 1b study of ALKS 2680 in narcolepsy were presented.
Alkermes (ALKS) reported strong Q3 2024 financial results with total revenues of $378.1 million. Net sales of proprietary products grew 18% year-over-year, with GAAP net income from continuing operations at $92.8 million. Key product performance includes LYBALVI revenues of $74.7 million (47% growth), ARISTADA at $84.7 million, and VIVITROL at $113.7 million (14% growth). The company maintains its 2024 financial guidance and continues to advance its pipeline, particularly ALKS 2680, its orexin 2 receptor agonist for narcolepsy treatment. During Q3, Alkermes repurchased approximately 4.4 million shares for $115.6 million, with $200 million remaining in the program.
Alkermes plc (Nasdaq: ALKS) has announced it will host a conference call and webcast presentation on Thursday, October 24, 2024, at 8:00 a.m. ET to discuss its third quarter financial results. The event will be accessible via the Investors section of Alkermes' website, with a webcast player and accompanying slides available. Participants can join the conference call by dialing +1 877 407 2988 (U.S. callers) or +1 201 389 0923 (international callers).
Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia.
Alkermes plc (Nasdaq: ALKS) has announced an investor event scheduled for October 9, 2024, at 10:00 a.m. EDT in Waltham, Mass. The event will focus on reviewing the company's orexin portfolio and development strategy. It will feature presentations by Alkermes' Research & Development team, followed by a clinician and thought leader panel discussion and a Q&A session.
The event will be accessible virtually via webcast, with registration available on the Investors section of Alkermes' website. A replay will be archived for 30 days following the presentation. Alkermes is a global biopharmaceutical company specializing in neuroscience, with a portfolio of commercial products for various mental health conditions and a pipeline of candidates for neurological disorders, including narcolepsy.
Alkermes plc (Nasdaq: ALKS) announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at Sleep Europe 2024. ALKS 2680 is an investigational, oral, selective orexin 2 receptor agonist for narcolepsy treatment. The company will share data from NT2 (n=9) and IH (n=8) patient cohorts, where ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo.
Alkermes will also present posters on the study design for ongoing phase 2 studies, Vibrance-1 and Vibrance-2, evaluating ALKS 2680 in narcolepsy type 1 and type 2 patients. The phase 1b study results support further clinical evaluation of ALKS 2680 as a potential treatment for sleep disorders with and without known orexin deficiency.